...
首页> 外文期刊>Clinics in liver disease >Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value.
【24h】

Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value.

机译:抗线粒体抗体和其他抗体在原发性胆汁性肝硬化中的诊断和预后价值。

获取原文
获取原文并翻译 | 示例
           

摘要

Antimitochondrial antibodies (AMA) are the serologic cornerstone in the diagnosis of primary biliary cirrhosis (PBC), even if they are not detectable in a proportion of patients, notwithstanding the most sensitive and sophisticated technologies used. To fill in the serologic gap in AMA-negative PBC, there is sound evidence to consider antinuclear antibody (ANA) patterns, such as anti-multiple nuclear dots and anti-membranous/rim-like, as PBC-specific surrogate hallmarks of the disease, and their detection can be considered virtually diagnostic. Furthermore, particular ANA specificities, such as anti-gp210, anti-p62, anticentromere antibodies, and anti-dsDNA, may provide additional diagnostic and prognostic information.
机译:抗线粒体抗体(AMA)是诊断原发性胆汁性肝硬化(PBC)的血清学基石,即使在一部分患者中无法检测到,尽管使用了最敏感和最先进的技术。为了填补AMA阴性PBC的血清学空白,有确凿的证据考虑将抗核抗体(ANA)模式(例如抗多核点和抗膜/边缘样)视为该疾病的PBC特异性替代标志。 ,其检测可以视为虚拟诊断。此外,特定的ANA特异性(例如抗gp210,抗p62,抗着丝粒抗体和抗dsDNA)可能会提供其他诊断和预后信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号